Genetic Engineering vaccines show promise.
ZyCoV-D vaccine which uses The three-dose has been found to prevent symptomatic disease in only 66% of those vaccinated, according to an interim study quoted by the vaccine maker Cadila Healthcare.
The new DNA vaccine, once administered, programs the body’s immune system to fight the actual virus.
- Cadila Healthcare plans to produce up to 120 million doses every year.
- Previous DNA vaccines have worked well in animals but not humans.
Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, India primarily engaged in the manufacture of generic drugs. It ranked 100th in the Fortune India 500 list in 2020.